Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial

This 2022 phase III randomized, double-blind study (PMID: 34634163) evaluated topical finasteride spray versus placebo and oral finasteride in 458 men with androgenetic alopecia over 24 weeks. Topical finasteride significantly increased hair count compared to placebo (20.2 vs. 6.7 hairs; p < 0.001) and performed comparably to oral finasteride in